Histone H3.3 and cancer: A potential reader connection

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 22, 2015, Pages 7067-7072

  Lan, Fei ^a,b   Shi, Yang ^c,d  

^a FUDAN UNIVERSITY   (China)

^b CHILDREN S HOSPITAL OF FUDAN UNIVERSITY   (China)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

BS69; Cancer; H3.3; H3.3K36me3; Histone

Indexed keywords

CENTROMERE PROTEIN A; HISTONE H3; ONCOPROTEIN; PROTEIN BS69; UNCLASSIFIED DRUG; CARRIER PROTEIN; HISTONE; ZMYND11 PROTEIN, HUMAN;

ALTERNATIVE RNA SPLICING; ARTICLE; ASTROCYTOMA; CANCER INHIBITION; CARCINOGENESIS; CELL DIFFERENTIATION; CHONDROBLASTOMA; CHROMATIN; GENE EXPRESSION; GIANT CELL TUMOR; HISTONE MODIFICATION; HUMAN; HUMAN GENOME; INTRON RETENTION; MISSENSE MUTATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; SEQUENCE HOMOLOGY; TRANSCRIPTION ELONGATION; BIOLOGICAL MODEL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE;

CARRIER PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; MODELS, BIOLOGICAL; MUTATION, MISSENSE; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY;

EID: 84930945065     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1418996111     Document Type: Article

References (66)

1. Tagami H, Ray-Gallet D, Almouzni G, Nakatani Y (2004) Histone H3.1 and H3.3 complexes mediate nucleosome assembly pathways dependent or independent of DNA synthesis. Cell 116(1):51-61.
2. Goldberg AD, et al. (2010) Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 140(5):678-691.
3. Drané P, Ouararhni K, Depaux A, Shuaib M, Hamiche A (2010) The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes Dev 24(12):1253-1265.
4. Ahmad K, Henikoff S (2002) The histone variant H3.3 marks active chromatin by replication-independent nucleosome assembly. Mol Cell 9(6):1191-1200.
5. Ray-Gallet D, et al. (2011) Dynamics of histone H3 deposition in vivo reveal a nucleosome gap-filling mechanism for H3.3 to maintain chromatin integrity. Mol Cell 44(6):928-941.
6. Chen P, et al. (2013) H3.3 actively marks enhancers and primes gene transcription via opening higher-ordered chromatin. Genes Dev 27(19):2109-2124.
7. Szenker E, Lacoste N, Almouzni G (2012) A developmental requirement for HIRAdependent H3.3 deposition revealed at gastrulation in Xenopus. Cell Reports 1(6):730-740.
8. Bush KM, et al. (2013) Endogenous mammalian histone H3.3 exhibits chromatinrelated functions during development. Epigenetics & chromatin 6(1):7.
9. Behjati S, et al. (2013) Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet 45(12):1479-1482.
10. Wu G, et al.; St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44(3):251-253.
11. Schwartzentruber J, et al. (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482(7384):226-231.
12. Sturm D, et al. (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22(4):425-437.
13. Buczkowicz P, et al. (2014) Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 46(5):451-456.
14. Fontebasso AM, et al. (2014) Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet 46(5):462-466.
15. Wu G, et al.; St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project (2014) The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 46(5):444-450.
16. Aihara K, et al. (2014) H3F3A K27M mutations in thalamic gliomas from young adult patients. Neuro-oncol 16(1):140-146.
17. Taylor KR, et al. (2014) Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet 46(5):457-461.
18. Bjerke L, et al. (2013) Histone H3.3 mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov 3(5):512-519.
19. Lewis PW, et al. (2013) Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340(6134):857-861.
20. Bender S, et al. (2013) Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 24(5):660-672.
21. Chan KM, et al. (2013) The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev 27(9):985-990.
22. Herz HM, et al. (2014) Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling. Science 345(6200):1065-1070.
23. Wen H, et al. (2014) ZMYND11 links histone H3.3K36me3 to transcription elongation and tumour suppression. Nature 508(7495):263-268.
24. Guo R, et al. (2014) BS69/ZMYND11 reads and connects histone H3.3 lysine 36 trimethylation-decorated chromatin to regulated pre-mRNA processing. Mol Cell 56(2):298-310.
25. Hateboer G, et al. (1995) BS69, a novel adenovirus E1A-associated protein that inhibits E1A transactivation. EMBO J 14(13):3159-3169.
26. Masselink H, Bernards R (2000) The adenovirus E1A binding protein BS69 is a corepressor of transcription through recruitment of N-CoR. Oncogene 19(12):1538-1546.
27. Ladendorff NE, Wu S, Lipsick JS (2001) BS69, an adenovirus E1A-associated protein, inhibits the transcriptional activity of c-Myb. Oncogene 20(1):125-132.
28. Velasco G, Grkovic S, Ansieau S (2006) New insights into BS69 functions. J Biol Chem 281(24):16546-16550.
29. Dhayalan A, et al. (2010) The Dnmt3a PWWP domain reads histone 3 lysine 36 trimethylation and guides DNA methylation. J Biol Chem 285(34):26114-26120.
30. Vezzoli A, et al. (2010) Molecular basis of histone H3K36me3 recognition by the PWWP domain of Brpf1. Nat Struct Mol Biol 17(5):617-619.
31. Li F, et al. (2013) The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSα. Cell 153(3):590-600.
32. Wang Y, et al. (2009) Regulation of Set9-mediated H4K20 methylation by a PWWP domain protein. Mol Cell 33(4):428-437.
33. Qin S, Min J (2014) Structure and function of the nucleosome-binding PWWP domain. Trends Biochem Sci 39(11):536-547.
34. Edmunds JW, Mahadevan LC, Clayton AL (2008) Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation. EMBO J 27(2):406-420.
35. Wen H, Li Y, Li H, Shi X (2014) ZMYND11: An H3.3-specific reader of H3K36me3. Cell Cycle 13(14):2153-2154.
36. Swartling FJ, et al. (2012) Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell 21(5):601-613.
37. Rahl PB, et al. (2010) c-Myc regulates transcriptional pause release. Cell 141(3):432-445.
38. Bartels C, Klatt C, Lührmann R, Fabrizio P (2002) The ribosomal translocase homologue Snu114p is involved in unwinding U4/U6 RNA during activation of the spliceosome. EMBO Rep 3(9):875-880.
39. Gunderson FQ, Johnson TL (2009) Acetylation by the transcriptional coactivator Gcn5 plays a novel role in co-transcriptional spliceosome assembly. PLoS Genet 5(10):e1000682.
40. Batsché E, Yaniv M, Muchardt C (2006) The human SWI/SNF subunit Brm is a regulator of alternative splicing. Nat Struct Mol Biol 13(1):22-29.
41. Hnilicová J, et al. (2011) Histone deacetylase activity modulates alternative splicing. PLoS ONE 6(2):e16727.
42. Shukla S, Oberdoerffer S (2012) Co-transcriptional regulation of alternative premRNA splicing. Biochim Biophys Acta 1819(7):673-683.
43. Li B, Howe L, Anderson S, Yates JR, 3rd, Workman JL (2003) The Set2 histone methyltransferase functions through the phosphorylated carboxyl-terminal domain of RNA polymerase II. J Biol Chem 278(11):8897-8903.
44. Huff JT, Plocik AM, Guthrie C, Yamamoto KR (2010) Reciprocal intronic and exonic histone modification regions in humans. Nat Struct Mol Biol 17(12):1495-1499.
45. Kim S, Kim H, Fong N, Erickson B, Bentley DL (2011) Pre-mRNA splicing is a determinant of histone H3K36 methylation. Proc Natl Acad Sci USA 108(33):13564-13569.
46. de Almeida SF, et al. (2011) Splicing enhances recruitment of methyltransferase HYPB/Setd2 and methylation of histone H3 Lys36. Nat Struct Mol Biol 18(9):977-983.
47. Spies N, Nielsen CB, Padgett RA, Burge CB (2009) Biased chromatin signatures around polyadenylation sites and exons. Mol Cell 36(2):245-254.
48. Bondarenko VA, et al. (2006) Nucleosomes can form a polar barrier to transcript elongation by RNA polymerase II. Mol Cell 24(3):469-479.
49. de la Mata M, et al. (2003) A slow RNA polymerase II affects alternative splicing in vivo. Mol Cell 12(2):525-532.
50. Ip JY, et al. (2011) Global impact of RNA polymerase II elongation inhibition on alternative splicing regulation. Genome Res 21(3):390-401.
51. Braunschweig U, et al. (2014) Widespread intron retention in mammals functionally tunes transcriptomes. Genome Res 24(11):1774-1786.
52. Bernstein BE, et al. (2006) A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125(2):315-326.
53. Wong JJ, et al. (2013) Orchestrated intron retention regulates normal granulocyte differentiation. Cell 154(3):583-595.
54. Yap K, Lim ZQ, Khandelia P, Friedman B, Makeyev EV (2012) Coordinated regulation of neuronal mRNA steady-state levels through developmentally controlled intron retention. Genes Dev 26(11):1209-1223.
55. Yu B, et al. (2009) BS69 undergoes SUMO modification and plays an inhibitory role in muscle and neuronal differentiation. Exp Cell Res 315(20):3543-3553.
56. Eswaran J, et al. (2013) RNA sequencing of cancer reveals novel splicing alterations. Scientific reports 3:1689.
57. Simon JM, et al. (2014) Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Genome Res 24(2):241-250.
58. Shapiro IM, et al. (2011) An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet 7(8):e1002218.
59. Duns G, et al. (2010) Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res 70(11):4287-4291.
60. Fontebasso AM, et al. (2013) Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol 125(5):659-669.
61. Zhang J, et al. (2012) The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481(7380):157-163.
62. Yang H, et al. (2010) Analysis of copy number variations of BS69 in multiple types of hematological malignancies. Ann Hematol 89(10):959-964.
63. Hake SB, et al. (2005) Serine 31 phosphorylation of histone variant H3.3 is specific to regions bordering centromeres in metaphase chromosomes. Proc Natl Acad Sci USA 102(18):6344-6349.
64. Jacob Y, et al. (2014) Selective methylation of histone H3 variant H3.1 regulates heterochromatin replication. Science 343(6176):1249-1253.
65. Wu H, et al. (2011) Structural and histone binding ability characterizations of human PWWP domains. PLoS ONE 6(6):e18919.
66. Szenker E, Ray-Gallet D, Almouzni G (2011) The double face of the histone variant H3.3. Cell Res 21(3):421-434.